Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer : updated analysis of the observational GioTag study
Authors:ID Hochmair, Maximilian J (Author)
ID Morabito, Alessandro (Author)
ID Hao, Desiree (Author)
ID Yang, Cheng-Ta (Author)
ID Soo, Ross A (Author)
ID Yang, James C-H (Author)
ID Gucalp, Rasim (Author)
ID Halmos, Balazs (Author)
ID Wang, Lara (Author)
ID Märten, Angela (Author)
ID Čufer, Tanja, Klinika Golnik, Medicinska fakulteta UL (Author)
Files:.pdf PDF - Presentation file, download (1,58 MB)
MD5: AE826F62EC54CB83F71667FE803EEB71
 
.pdf PDF - Supplement, download (1,10 MB)
MD5: 501E9A968487DEB2D03082EAB847B278
 
URL URL - Source URL, visit https://www.futuremedicine.com/doi/full/10.2217/fon-2019-0346
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
Abstract:Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Results: Median OS was 41.3 months (90% CI: 36.8-46.3) overall and 45.7 months (90% CI: 45.3-51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8-30.3). Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors.
Keywords:non-small cell lung carcinoma - therapy, drug therapy, afatinib, osimertinib, GioTag study
Publication status:Published
Publication version:Version of Record
Place of publishing:Velika Britanija
Publisher:Future Medicine Ltd
Year of publishing:2019
Number of pages:str. 2905-2914
Numbering:Vol. 15, iss. 25
PID:20.500.12556/DiRROS-12417 New window
UDC:616.2
ISSN on article:1744-8301
DOI:10.2217/fon-2019-0346 New window
COBISS.SI-ID:2048610929 New window
Copyright:© 2019 Maximilian J Hochmair
Note:Nasl. z nasl. zaslona; Soavtorica iz Slovenije: Tanja Cufer; Opis vira z dne 10. 1. 2020;
Publication date in DiRROS:11.09.2020
Views:1369
Downloads:999
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Future oncology
Publisher:Future Medicine
ISSN:1744-8301
COBISS.SI-ID:521824025 New window

Licences

License:CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.
Licensing start date:23.07.2019

Secondary language

Language:Undetermined
Keywords:nedrobnocelični karcinom pljuč - terapija, terapija z zdravili, afatinib, osimertinib, raziskava GioTag


Back